![](https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-997048118%20%282%29.jpg?VersionId=kkCy_GPA._kNHOrrdTsV42Mpa7WgZ.Em)
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small …